top of page
ID11916 is unique as it is the first drug that combines AR antagonism and phosphodiesterase type 5 (PDE5) inhibition into one small molecule targeting androgen receptor over-expressed solid tumors. ID11916 has an improved anti-cancer effect that overcomes the limitations of pre-existing anti-AR. It is currently under pre-clinical development.
bottom of page